Universe Pharmaceuticals Inc. (UPC)
Healthcare
- Fundamental
- 2
- Sentiment
- 4
- Technical
- 3
Do Nothing: fundamentalScore is 2 (below required floor of 3); strategy requires fundamentalScore >= 3 before any bullish entry.
Company overview
Universe Pharmaceuticals Inc. focuses on the production and sale of traditional Chinese medicine products in China. The company also distributes biomedical drugs, medical instruments, and dietary supplements. It serves a broad range of clients including pharmaceutical companies, hospitals, and drugstore chains.
Fundamental
weakUniverse Pharmaceuticals shows declining revenue and ongoing losses, indicating weak fundamentals.
UPC is a tiny China-focused pharma/TCM business with shrinking sales (FY2025 revenue $17.9M, -22% YoY) and continued losses (FY2025 net margin -20.6%) with negative free cash flow (FCF yield about -77%). Liquidity is strong (cash ~$33.6M; net cash ~$24.3M; current ratio ~4.1), but the latest Form 20-F highlights recurring losses/going-concern discussion and PRC regulatory risks, and a June 2026 6-K announced a share-funded acquisition that can be materially dilutive. Overall: speculative with elevated downside risk.
Sentiment
goodSentiment is moderately positive following the recent acquisition announcement.
Primary near-term catalyst is the 2026-06-26 announced acquisition/patent-portfolio expansion (bullish, announced), which is driving limited but positive media coverage in the last ~14 days. Sentiment delta vs the 30–90d baseline is indeterminate due to sparse on-topic older coverage; legal screens show no active cases/investigations and retail signal is indeterminate due to Reddit rate-limiting.
Technical
fairThe technicals indicate a stretched, high-volatility tape with recent explosive price movements.
The chart shows an explosive upside regime change: price is far above SMA20/50/200 and EMA9/21, MACD is positive above its signal, and ADX confirms strong trend strength. The counterweight is execution quality—RSI14 at 91.56, atr14 at 1.37 (roughly 11%-12% of price), and the latest session fading below the 13.68 daily VWAP after a vertical spike all point to a stretched, high-volatility tape rather than a clean low-risk swing entry.
You’re looking at 2026-06-29 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.